{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:44:24Z","timestamp":1770450264091,"version":"3.49.0"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,2,14]]},"abstract":"<jats:p> PURPOSE: A first comparative trial of fludarabine (FLU) alone versus FLU plus idarubicin (FLU-ID) for indolent or mantle-cell lymphomas. <\/jats:p><jats:p> PATIENTS AND METHODS: From September 1995 to July 1998, 199 patients aged 25 to 65 years (median, 54 years) with newly diagnosed stages II to IV indolent or mantle-cell lymphomas (standard risk according to the International Prognostic Index) were enrolled onto a multicenter, 1:1 randomized study. Of the 199 patients who were able to be assessed, 101 were assigned to the FLU group (six monthly cycles of FLU 25 mg\/m<jats:sup>2<\/jats:sup>\/d on days 1 through 5) and 98 to the FLU-ID group (six monthly cycles of FLU 25 mg\/m<jats:sup>2<\/jats:sup>\/d on days 1 through 3 and idarubicin 12 mg\/m<jats:sup>2<\/jats:sup> on day 1). <\/jats:p><jats:p> RESULTS: In the FLU group, complete response (CR) and partial response rates were 47% and 37%, respectively, whereas in the FLU-ID group, they were 39% and 42%, respectively. In-depth analysis of the CR rate with respect to histologic type showed that FLU seemed to be superior to FLU-ID in treating follicular lymphomas (60% v 40%, respectively), whereas FLU-ID seemed to be more effective than FLU in treating nonfollicular lymphomas (small lymphocytic, 43% v 29%, respectively; immunocytoma, 38% v 23%, respectively; P = not significant), excluding the mantle-cell subset (in which there was no difference between the two groups). No striking differences were observed between the two protocols in terms of overall response or toxicity, which was generally mild. However, with a median follow-up of 19 months, only 29 patients (62%) who received FLU alone have maintained their initial CR, compared with 32 (84%) of those who received FLU-ID therapy (P = .021). <\/jats:p><jats:p> CONCLUSION: Although the FLU-ID regimen may not significantly improve the induction of CR in most indolent-lymphoma patients, our preliminary data do suggest that, with respect to FLU alone, it may be capable of conferring a longer-lasting CR and that it might be superior in terms of CR rate in small lymphocytic and immunocytoma subtypes. <\/jats:p>","DOI":"10.1200\/jco.2000.18.4.773","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:02:08Z","timestamp":1487919728000},"page":"773-773","source":"Crossref","is-referenced-by-count":71,"title":["Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma"],"prefix":"10.1200","volume":"18","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Magagnoli","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Moretti","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"De Renzo","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Battista","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Zaccaria","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Guardigni","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marra","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fioravante","family":"Ronconi","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito Michele","family":"Lauta","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bendandi","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Gherlinzoni","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Gentilini","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Ciccone","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cellini","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ricciuti","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology and University of BolognaBologna; Division of Hematology, Pesaro Hospital, Pesaro; Division of Hematology, University of Napoli, Napoli; Division of Hematology, Dolo Hospital, Dolo; Division of Hematology, Ravenna Hospital, Ravenna; Division of Hematology, Cesena Hospital, Cesena; Division of Hematology, Taranto Hospital, Taranto; Division of Hematology, La Cattolica University of Roma, Roma; Division of Internal Medicine, University of Bari, Bari;..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"R2-0117","unstructured":"Young  RC,  Longo  DL,  Glatstein  E, et al:  The treatment of indolent lymphomas:  Watchful waiting versus aggressive combined modality treatment. Semin Hematol 25:11,1988-16,"},{"key":"R3-0117","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058904"},{"key":"R4-0117","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G"},{"key":"R5-0117","unstructured":"Zinzani  PL,  Magagnoli  M,  Gherlinzoni  F, et al:  To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center.  Haematologica 83:502,1998-507,"},{"key":"R6-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.644"},{"key":"R7-0117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780"},{"key":"R8-0117","doi-asserted-by":"crossref","unstructured":"Redman  JR,  Cabanillas  F,  Velasquez  WS, et al:  Phase II trial of fludarabine phosphate in lymphoma:  An effective new agent in low-grade lymphoma. J Clin Oncol 109:790,1992-794,","DOI":"10.1200\/JCO.1992.10.5.790"},{"key":"R9-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"R10-0117","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058591"},{"key":"R11-0117","unstructured":"Hiddeman  W,  Unterhalt  M,  Pott  C, et al:  Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin\u2019s lymphomas:  A phase II study of the German Low-Grade Non-Hodgkin\u2019s Lymphoma Study Group. Semin Oncol 20:28,1993-31,"},{"key":"R12-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.514"},{"key":"R13-0117","unstructured":"Pigaditou  A,  Rohatiner  AZ,  Whelan  JS, et al:  Fludarabine in low-grade lymphoma.  Semin Oncol 20:24,1993-27,   (suppl 7)"},{"key":"R14-0117","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.253"},{"key":"R15-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.575"},{"key":"R16-0117","doi-asserted-by":"crossref","unstructured":"Zinzani  PL,  Bendandi  M,  Tura  S:  FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin\u2019s lymphoma.  Eur J Haematol 55:262,1995-266,","DOI":"10.1111\/j.1600-0609.1995.tb00269.x"},{"key":"R17-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"R18-0117","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008228709612"},{"key":"R19-0117","unstructured":"Zinzani  PL,  Bendandi  M,  Gherlinzoni  F, et al:  FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin\u2019s lymphoma.  Haematologica 81:168,1996-171,"},{"key":"R20-0117","unstructured":"Hochster  H,  Oken  M,  Bennet  J, et al:  Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin\u2019s lymphomas (NHL)-ECOG 1491.  Blood 84:383,1994  (abstr)"},{"key":"R21-0117","doi-asserted-by":"crossref","unstructured":"Lazzarino  M,  Orlandi  E,  Montillo  M, et al:  Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin\u2019s lymphoma.  Ann Oncol 10:59,1999-64,","DOI":"10.1023\/A:1008376728894"},{"key":"R22-0117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R23-0117","unstructured":"Carbone  PP,  Kaplan  HS,  Musshoff  K, et al:  Report of the Committee on Hodgkin\u2019s Disease Staging Classification.  Cancer Res 31:1860,1971-1861,"},{"key":"R24-0117","unstructured":"Shipp  M,  Harrington  D,  Anderson  J, et al:  A predictive model for aggressive non-Hodgkin\u2019s lymphoma.  N Engl J Med 329:1471,1993-1475,"},{"key":"R25-0117","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"R26-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R27-0117","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R28-0117","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780010204"},{"key":"R29-0117","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"R30-0117","unstructured":"Mantel  N,  Haenszel  W:  Statistical aspects of the analysis of data from retrospective studies of diseases.  J Natl Cancer Inst 22:209,1959-222,"},{"key":"R31-0117","unstructured":"Hagenbeek  A,  Eghbali  H,  Monfardini  S, et al:  Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stage III and IV low grade malignant non-Hodgkin\u2019s lymphomas:  Preliminary results for a prospective, randomized phase III clinical trial in 381 patients. Blood 92:315a,1998  (abstr)"},{"key":"R32-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"R33-0117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"R34-0117","unstructured":"Zinzani  PL,  Magagnoli  M,  Moretti  L, et al:  Fludarabine-based chemotherapy in untreated mantle cell lymphomas:  An encouraging experience in 29 patients. Haematologica 84:1002,1999-1006,"},{"key":"R35-0117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.1997.tb00321.x"},{"key":"R36-0117","unstructured":"Foussard  C,  Deconinck  E,  Desablens  B, et al:  A randomized trial of fludarabine, mitoxantrone (FM) versus doxorubicin, cyclophosphamide, vindesine, prednisone (CHEP) as first line treatment in patients with advanced low-grade lymphoma (LG-NHL):  A multicenter study by GOLEAMS Group. Blood 92:316a,1998  (abstr)"},{"key":"R37-0117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.12.3449.3449"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.4.773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:38:04Z","timestamp":1653514684000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.4.773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,14]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,2,14]]}},"alternative-id":["10.1200\/JCO.2000.18.4.773"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.4.773","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2,14]]}}}